Gómez Cibera, EmilioIvanovic Barbeito, YerkoGutiérrez Martínez, EduardoMorales Ruiz, EnriqueAbradelo De Usera, ManuelHilario Barrio, AmayaRamos González, AnaRuíz Morales, JuanVillarejo Galende, Alberto2025-01-222025-01-222015-12-30Gómez-Cibeira E, Ivanovic-Barbeito Y, Gutiérrez-Martínez E, Morales E, Abradelo M, Hilario A, Ramos A, Ruiz-Morales J, Villarejo-Galende A. Eculizumab-related progressive multifocal leukoencephalopathy. Neurology. 2016 Jan 26;86(4):399-400. doi: 10.1212/WNL.0000000000002312. Epub 2015 Dec 30. PMID: 26718572; PMCID: PMC4776092.10.1212/WNL.0000000000002312https://hdl.handle.net/20.500.14352/115594Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the CNS caused by reactivation of the polyomavirus JC (JCV). In the context of immunosuppression, JCV can reactivate and spread to brain infecting oligodendrocytes. Eculizumab is a first-in-class humanized monoclonal antibody developed to target the cleavage of C5, preventing the release of C5a and activation of the terminal complement pathway. It has been shown to be effective in the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). Eculizumab can impair neutro- phil and monocyte functions and predispose to encapsulated bacteria infections. We report the novel finding of PML in a patient receiving eculizumab.engjournal articlehttps://doi.org/10.1212/WNL.0000000000002312PMC4776092https://www.neurology.org/doi/10.1212/WNL.0000000000002312restricted access616-073.7Leucoencefalopatia multifocal progresivaRMEculizumabDiagnóstico por imagen y medicina nuclear3201.11 Radiología